{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:12:49Z","timestamp":1779207169428,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04152-0","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:09:17Z","timestamp":1767492557000},"page":"2428-2434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer"],"prefix":"10.1007","volume":"28","author":[{"given":"Justin","family":"Battaglini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"AlDoughaim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sita","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Everett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey R.","family":"Oxnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-3004","authenticated-orcid":false,"given":"Umit","family":"Tapan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"11","key":"4152_CR1","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.3390\/cancers15112998","volume":"15","author":"SL Feldt","year":"2023","unstructured":"Feldt SL, Bestvina CM. The role of MET in resistance to EGFR inhibition in NSCLC: a review of mechanisms and treatment implications. Cancers (Basel). 2023;15(11):2998. https:\/\/doi.org\/10.3390\/cancers15112998. (PMID: 37296959; PMCID: PMC10251884).","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4152_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100534","volume":"4","author":"I Dagogo-Jack","year":"2023","unstructured":"Dagogo-Jack I, Kiedrowski LA, Heist RS, Lin JJ, Meador CB, Krueger EA, et al. Efficacy and tolerability of ALK\/MET combinations in patients with ALK-rearranged lung cancer with acquired MET amplification: a retrospective analysis. JTO Clin Res Rep. 2023;4(8):100534. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100534. (PMID: 37533439; PMCID: PMC10391652).","journal-title":"JTO Clin Res Rep"},{"issue":"16","key":"4152_CR3","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-22-2189","volume":"29","author":"J Rotow","year":"2023","unstructured":"Rotow J, Patel JD, Hanley MP, Yu H, Awad M, Goldman JW, et al. Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers. Clin Cancer Res. 2023;29(16):2979\u201387. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2189. (PMID: 36996322; PMCID: PMC10524391).","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4152_CR4","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.1038\/s41467-022-33210-2","volume":"13","author":"Y Kobayashi","year":"2022","unstructured":"Kobayashi Y, Oxnard GR, Cohen EF, Mahadevan NR, Alessi JV, Hung YP, et al. Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors. Nat Commun. 2022;13(1):5614. https:\/\/doi.org\/10.1038\/s41467-022-33210-2. (PMID: 36153311; PMCID: PMC9509394).","journal-title":"Nat Commun"},{"key":"4152_CR5","doi-asserted-by":"publisher","first-page":"1611715","DOI":"10.3389\/pore.2024.1611715","volume":"30","author":"G G\u00e1lffy","year":"2024","unstructured":"G\u00e1lffy G, Mor\u00f3cz \u00c9, Korompay R, H\u00e9cz R, Bujdos\u00f3 R, Pusk\u00e1s R, et al. Targeted therapeutic options in early and metastatic NSCLC-overview. Pathol Oncol Res. 2024;30:1611715. https:\/\/doi.org\/10.3389\/pore.2024.1611715. (PMID: 38605928; PMCID: PMC11006988).","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"4152_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11912-017-0587-4","volume":"19","author":"JK Sabari","year":"2017","unstructured":"Sabari JK, Santini F, Bergagnini I, Lai WV, Arbour KC, Drilon A. Changing the therapeutic landscape in non-small cell lung cancers: the evolution of comprehensive molecular profiling improves access to therapy. Curr Oncol Rep. 2017;19(4):24. https:\/\/doi.org\/10.1007\/s11912-017-0587-4. (PMID: 28303491; PMCID: PMC6428198.S).","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"4152_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","volume":"17","author":"J Rotow","year":"2017","unstructured":"Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637\u201358. https:\/\/doi.org\/10.1038\/nrc.2017.84. (PMID: 29068003).","journal-title":"Nat Rev Cancer"},{"key":"4152_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100140","volume":"4","author":"A Desai","year":"2024","unstructured":"Desai A, Pasquina LW, Nulsen C, Keller-Evans RB, Mata DA, Tukachinsky H, et al. Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases. J Liq Biopsy. 2024;4:100140. https:\/\/doi.org\/10.1016\/j.jlb.2024.100140. (PMID: 40027147; PMCID: PMC11863816).","journal-title":"J Liq Biopsy"},{"issue":"15","key":"4152_CR9","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/cncr.29397","volume":"121","author":"PC Lo","year":"2015","unstructured":"Lo PC, Dahlberg SE, Nishino M, Johnson BE, Sequist LV, Jackman DM, et al. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015;121(15):2570\u20137. https:\/\/doi.org\/10.1002\/cncr.29397. (Epub 2015 Apr 15. PMID: 25876525; PMCID: PMC4525718).","journal-title":"Cancer"},{"issue":"4","key":"4152_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","volume":"31","author":"GR Oxnard","year":"2020","unstructured":"Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31(4):507\u201316. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.013. (Epub 2020 Jan 24. PMID: 32139298).","journal-title":"Ann Oncol"},{"key":"4152_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00818","volume":"9","author":"JW Riess","year":"2025","unstructured":"Riess JW, de Langen AJ, Ponce S, Goldberg SB, Piotrowska Z, Goldman JW, et al. ORCHARD: osimertinib plus necitumumab in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer with a secondary epidermal growth factor receptor alteration whose disease had progressed on first-line osimertinib. JCO Precis Oncol. 2025;9:e2400818. https:\/\/doi.org\/10.1200\/PO-24-00818. (Epub 2025 Jun 4 PMID: 40466026).","journal-title":"JCO Precis Oncol"},{"issue":"15","key":"4152_CR12","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1158\/1078-0432.CCR-20-4604","volume":"27","author":"AB Cortot","year":"2021","unstructured":"Cortot AB, Madroszyk A, Giroux-Leprieur E, Molinier O, Quoix E, B\u00e9rard H, et al. First-line afatinib plus cetuximab for EGFR-mutant non-small cell lung cancer: results from the randomized phase II IFCT-1503 ACE-lung study. Clin Cancer Res. 2021;27(15):4168\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4604. (Epub 2021 May 24 PMID: 34031056).","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4152_CR13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","volume":"25","author":"YL Wu","year":"2024","unstructured":"Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, et al. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2024;25(8):989\u20131002. https:\/\/doi.org\/10.1016\/S1470-2045(24)00270-5. (Erratum in: Lancet Oncol. 2024 Oct;25 (10):e472. 10.1016\/S1470-2045(24)00509-6. PMID: 39089305).","journal-title":"Lancet Oncol"},{"issue":"3","key":"4152_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"LV Sequist","year":"2020","unstructured":"Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(19)30785-5. (Epub 2020 Feb 3. PMID: 32027846).","journal-title":"Lancet Oncol"},{"issue":"2","key":"4152_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10637-020-01010-4","volume":"39","author":"JJ Yang","year":"2021","unstructured":"Yang JJ, Fang J, Shu YQ, Chang JH, Chen GY, He JX, et al. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Invest New Drugs. 2021;39(2):477\u201387. https:\/\/doi.org\/10.1007\/s10637-020-01010-4. (Epub 2020 Oct 14 PMID: 33052556).","journal-title":"Invest New Drugs"},{"key":"4152_CR16","doi-asserted-by":"publisher","first-page":"PO.20.00279","DOI":"10.1200\/PO.20.00279","volume":"1","author":"CE McCoach","year":"2021","unstructured":"McCoach CE, Yu A, Gandara DR, Riess JW, Vang DP, Li T, et al. Phase I\/II study of capmatinib plus erlotinib in patients with MET-positive non-small-cell lung cancer. JCO Precis Oncol. 2021;1:PO.20.00279. https:\/\/doi.org\/10.1200\/PO.20.00279. (PMID: 34036220; PMCID: PMC8140807).","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"4152_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jtho.2016.09.131","volume":"12","author":"SI Ou","year":"2017","unstructured":"Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, et al. Phase I results from a study of crizotinib in combination with erlotinib in patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2017;12(1):145\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2016.09.131. (Epub 2016 Sep 30. PMID: 27697581; PMCID: PMC7249761).","journal-title":"J Thorac Oncol"},{"issue":"5","key":"4152_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jtho.2016.01.022","volume":"11","author":"PA J\u00e4nne","year":"2016","unstructured":"J\u00e4nne PA, Shaw AT, Camidge DR, Giaccone G, Shreeve SM, Tang Y, et al. Combined pan-HER and ALK\/ROS1\/MET inhibition with dacomitinib and crizotinib in advanced non-small cell lung cancer: results of a phase I study. J Thorac Oncol. 2016;11(5):737\u201347. https:\/\/doi.org\/10.1016\/j.jtho.2016.01.022. (Epub 2016 Feb 18. PMID: 26899759).","journal-title":"J Thorac Oncol"},{"issue":"14","key":"4152_CR19","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.3390\/cancers16142589","volume":"16","author":"I Attili","year":"2024","unstructured":"Attili I, Corvaja C, Spitaleri G, Trillo Aliaga P, Del Signore E, Passaro A, et al. Post-progression analysis of EGFR-mutant NSCLC following osimertinib therapy in real-world settings. Cancers (Basel). 2024;16(14):2589. https:\/\/doi.org\/10.3390\/cancers16142589. (PMID: 39061227; PMCID: PMC11274531).","journal-title":"Cancers (Basel)"},{"issue":"10","key":"4152_CR20","doi-asserted-by":"publisher","first-page":"105807","DOI":"10.1016\/j.esmoop.2025.105807","volume":"10","author":"N Peled","year":"2025","unstructured":"Peled N, Tufman A, Sequist LV, Pasello G, Wang Q, Antonuzzo L, et al. COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib. ESMO Open. 2025;10(10):105807. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105807. (Epub 2025 Sep 8. PMID: 41139117; PMCID: PMC12573503).","journal-title":"ESMO Open"},{"issue":"2","key":"4152_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jtho.2019.10.014","volume":"15","author":"JJ Lin","year":"2020","unstructured":"Lin JJ, Schoenfeld AJ, Zhu VW, Yeap BY, Chin E, Rooney M, et al. Efficacy of platinum\/pemetrexed combination chemotherapy in ALK-positive NSCLC refractory to second-generation ALK inhibitors. J Thorac Oncol. 2020;15(2):258\u201365. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.014. (Epub 2019 Oct 26. PMID: 31669591; PMCID: PMC7058505).","journal-title":"J Thorac Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04152-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:32:19Z","timestamp":1779204739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04152-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4152"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04152-0","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}